Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 23

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on Treating Resistant Viral Infections in Stem Cell Transplant Patients Using Allogeneic Multivirus-Specific T Cells

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allogeneic Cd4+ And Cd8+ T Lymphocytes Ex Vivo Incubated With Synthetic Peptides Of The Viral Antigens Of Cytomegalovirus, Adenovirus And Epstein-Barr Virus
  • Sponsor:Medical Center - University Of Freiburg

Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol
  • Sponsor:Neurothera Labs Inc.

Ischaemic stroke+1

Recruiting

Study on High-Dose Methylprednisolone and Prednisolone for Children with Stroke Due to Focal Cerebral Arteriopathy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Prednisolone
  • Sponsor:Insel Gruppe AG

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Polyneuropathy

Recruiting

Study on Aconite Pain Oil to Prevent and Reduce Symptoms of Chemotherapy-Induced Polyneuropathy in Cancer Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Wala-Heilmittel GmbH

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Sotatercept for Children with Pulmonary Arterial Hypertension Receiving Standard Care

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.